Compare Allstate Corp (ALL) vs Biogen Inc (BIIB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Allstate Corp vs Biogen Inc — how do they compare? Allstate Corp trades at $252.97 (market cap $64.77B), while Biogen Inc trades at $203.64 (market cap $29.40B). The key difference: Allstate Corp is far larger — about 2.2× Biogen Inc's market cap, and Allstate Corp pays a 1.72% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| ALL | BIIB | |
|---|---|---|
Market Cap | $64.77B | $29.40B |
Sector | Financials | Health |
52-Week High | $251.61 | $216.63 |
52-Week Low | $190.00 | $122.68 |
Enterprise Value | $73.56B | $31.68B |
Dividend Yield | 1.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $251.61, up 1.19% on the day, with a bullish technical outlook and strong fundamental momentum. The stock shows robust earnings beats in recent quarters, a low P/E of 5.57, and a high ROE of 48.44%. Recent news highlights dividend declarations and anticipation for Q2 2026 earnings, with analysts citing improved underwriting and catastrophe performance as key drivers.
The outlook remains positive given valuation discounts and earnings growth, but risks include hurricane season exposure and competitive pressures. Upside potential is supported by a consensus price target of $251.18, with Wall Street largely holding a buy or neutral stance, though near-term volatility may arise from earnings results due August 6, 2026.
Biogen (BIIB) trades at $199.15, up 0.12% on the day, with a bullish technical signal from moving averages and RSI near oversold levels at 20.73. The company reported Q1 2026 EPS of $3.57, beating estimates of $3.05, continuing a trend of earnings surprises. Revenue for 2025 was $9.89B with a net income margin of 13.81%, while recent acquisitions like RayThera for up to $1B aim to bolster its immunology pipeline. Analyst consensus price target is $226.00, implying potential upside from current levels.
BIIB presents a mixed outlook with strong earnings momentum and strategic acquisitions offset by legacy drug sales declines and legal investigations. The stock's valuation at a P/E of 21.41 is reasonable relative to growth prospects, but investors face risks from pipeline execution and competitive pressures in biotech. Near-term catalysts include Alzheimer's data presentations at AAIC 2026 in July.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
